Clinical evaluation of pravastatin in the treatment of type II hyperlipidemia in patients with non-insulin-dependent diabetes mellitus.
The study was conducted on 30 NIDDM patients with type II hyperlipoproteinemia. They consisted of 13 males and 17 females with the mean (+/- S.D.) age of 60.6 +/- 7.6 year. They were treated with a daily dose of 10 mg pravastatin given orally twice a day for 16 weeks. Their mean (+/- S.D.) serum TC, LDL-C, TG and HDL-C levels at week 0 were 259.7 +/- 22.6, 177.4 +/- 20.3, 173.9 +/- 62.3 and 44.0 +/- 9.9 mg/dl respectively. After receiving pravastatin the maximal reduction of TC, LDL-C and TG was 22.9, 31.2 and 17.1 per cent with statistical significant difference from the baseline. The maximal increment of HDL-C was 11.9 per cent, also showing statistical significant difference from the baseline. Plasma glucose, serum fructosamine and glycated hemoglobin were not affected by pravastatin. There were no significant changes in the patients' body weight and other biochemical parameters except for one case who had transient slight increase in transaminase during pravastatin treatment. These results indicate that pravastatin is an effective and safe drug in diabetic patients with hypercholesterolemia.
Deerochanawong
C
C
Department of Medicine, Rajavithi Hospital, Bangkok, Thailand.
Serirat
S
S
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D017035:Pravastatin